Healthcare

Meet your Healthcare Research team

CVS Group

CMA provisionally launching a formal market investigation

The Competition and Markets Authority (CMA) announced yesterday (March 12th) that its initial review into the vets market has identified multiple concerns. It has provisionally launched...

CVS Group

H1 2024 results reflect another period of good growth

Following the trading statement on January 25th, CVS has reported interim results to December 31st that reflect strong like-for-like top-line growth and an EBITDA margin of 19.1%, both...

Uniphar

FY2023 results reflect strong organic gross profit growth

Uniphar’s FY2023 results reflect strong organic growth in gross profits of 5.6% year-on-year (yoy). Adjusted EBITDA expanded 18% yoy. Higher interest costs and depreciation charges...

hVIVO

Trading update

hVIVO’s trading update for the year ending December 31st reflects stronger than expected results driven by strong margins. The outlook for 2024 is very positive with 90% revenue...

Uniphar

Trading statement

Uniphar’s trading statement to the end December 31st highlights a strong year of operating results. We are maintaining our forecasts. The outlook for 2024 is very positive and we...

Malin Corporation

CG Oncology IPO drives NAV growth

Malin has announced that one of its investments, CG Oncology, will list on the NASDAQ today following its initial public offering (IPO). Based on pricing, the value of the group’s existing...

CVS Group

H1 2024 trading statement

CVS has reported strong revenue growth of 11.4% year-on-year (yoy) and an EBITDA margin of 19.0% in its trading statement for H1 2024 to December 31st. These figures are in line with...

CVS Group

Trading update ahead of AGM

CVS has issued a trading statement, covering the first four months of its H1 2024 to end-October, ahead of its AGM today. Revenue growth and the EBITDA margin are in line with...

hVIVO

Specialist in human challenge trials

We are re-initiating coverage of hVIVO (HVO) with an ‘Outperform’ rating and a price target of 29p per share. Our investment thesis hinges on the robust industry growth outlook. HVO...

Uniphar

H1 results plus ambitious new targets and a new divisional structure

Uniphar has reported H1 2023 results with strong growth in gross profit and expects to meet market expectations for FY2023. The company has announced an ambitious new target of...